Navigation Links
Drugs.com Releases Q2 Sales for Top 100 U.S. Prescription Drugs: Humira Climbs into Top 5 and Posts Double-Digit Growth
Date:8/14/2013

NEW YORK, Aug. 14, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released second quarter 2013 U.S. prescription sales data for the top 100 drugs. Since Q2 2012, Otuska's antipsychotic Abilify and AstraZeneca's acid reducer Nexium have held either the number one or two spot in top dollar sales. This quarter, both agents continue to maintain their stronghold; each posts close to $1.5 billion in sales. Humira, AbbVie's key tumor necrosis factor (TNF) blocker, climbs three notches and sees a double-digit gain for the quarter.

(Photo: http://photos.prnewswire.com/prnh/20130814/PH63256-a )
(Photo: http://photos.prnewswire.com/prnh/20130814/PH63256-b )

Top Five Drugs by Sales, Q2 2013Drug NameSales ($000)% Change (previousquarter)Abilify

$1,597,913

+4.70%Nexium

$1,454,048

-0.34%Humira

$1,341,759

+10.22%Cymbalta

$1,338,912

+3.24%Crestor

$1,290,913

-0.37%The move of Humira into the top five shifts both Eli Lilly's Cymbalta, and AstraZeneca's Crestor down one position. Cymbalta, which reaped over $4.4 billion in 2012 U.S. sales, goes off patent this December.

Top Five Sales Gains, Q2 2013Drug NameGain ($000)% Change (previousquarter)Humira

$124,407

+10.22%doxycycline

$89,309

+46.22%Enbrel

$72,681

+6.76%Abilify

$71,685

+4.70%Epogen

$47,324

+9.40%Not only does Humira re-enter the top five drugs by sales, it also comes in at the number one spot in terms of sales growth. Enbrel, another TNF blocker, returns to positive growth after a slight drop in Q1. Abilify and Epogen round out the fourth and fifth spots in quarterly sales gains.

"The significant impact of TNF blockers on autoimmune disease activity is not only reflected in their varied indications such as rheumatoid arthritis, psoriasis and Crohn's disease, but also in their steady sales growth," said Philip Thornton, CEO of Drugs.com. "Since the second quarter of 2012, Humira, Enbrel, and Remicade have all placed in the top ten with revenues in the $1 billion range."

Top Five Sales Losses, Q2 2013 Drug NameLoss ($000)% Change (previousquarter)Avonex Pen

-$154,859

-45.78%Suboxone

-$78,819

-18.95%Advair Diskus

-$35,740

-2.80%Avonex

-$32,162

-9.51%modafinil

-$31,418

-14.37%Newer oral multiple sclerosis (MS) agents such as Novartis' Gilenya may now be impacting the use of injectable interferon such as Biogen Idec's Avonex, which loses significant growth this quarter. However, the news may not be all bad -- Biogen Idec also manufactures Tecfidera, the newest oral MS drug -- predicted to draw in over $3.5 billion in annual sales by 2017. Modafinil lost over 17 percent in sales gains in Q1 2013, and continues to slide this quarter.

Reckitt Benckiser's Suboxone for opiate dependence, now available only in the oral dissolvable film, drops close to $79 million. The sublingual tablet formulation of Suboxone, discontinued in March, can now be replaced with the generic version approved in February.

Detailed data on the top 100 drugs can be accessed at: http://www.drugs.com/stats/top100/sales

About Drugs.com
Drugs.com is the leading online drug information resource with over nine million unique visitors per month (ComScore, June 2013). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, Drugs.com empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as personal medication records, a drug interaction checker, pill identification wizard, symptom checker, pharma sales statistics and more.

For more information, visit: http://www.drugs.com/

Media Inquiries:
Drugs.com Press Officer
Email
(718) 395 2473

Read more news from Drugs.com.

 


'/>"/>
SOURCE Drugs.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Drugs.com Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season Boosts Numbers for Tamiflu
2. Drugs.com Launches iOS and Android Mobile App to Empower Patients and Providers Alike
3. Drugs.com Releases Q4 Sales for Top 100 U.S. Drugs
4. Drugs.com Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium and Abilify Remain the Leading Brands
5. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
6. Raritan Releases Dynamic Search User Interface on Amazon Web Services (AWS) Marketplace
7. Nutrastar Releases Second Quarter 2013 Results
8. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2013 Results
9. Bekers Hospital Review Releases Report on State of Hospital Industry
10. Beckers Healthcare Releases Report on State of ASC Industry
11. Earnings Releases, Investment Plans, Commencement of Clinical Trials, and FDA Applications Brighten Outlook - Research Report on Bard, Centene, Exact Sciences, Ironwood, and Merrimack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... The American Pharmacists Association (APhA) is excited ... Medically Underserved Areas Enhancement Act (H.R. 592) ... was previously introduced in the 114 th session ... through pharmacists and their patient care services. ... (R-KY), G.K. Butterfield (D-NC), Tom ...
(Date:1/23/2017)... , January 23, 2017 Ahead of ... to see how they have fared at the close: Kite Pharma ... Inc. (NASDAQ: OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... Biotechnology shares were relative laggards on Friday, January 20 th , ... our complimentary research reports on these stocks now at: ...
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries are factors ... BCC Research reveals in its new report that markets in developing ... strong growth due to rising government healthcare spending, increased levels of healthcare ... Reading ... BCC ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... Wooden and plastic balance boards have been around since at least ... Kumo Board is the first and only balance board to use a patent-pending design ... rigid at the same time as well as skill-level adjustable for all ages and abilities. ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate ... about the benefits of making new water infrastructure a number one priority. “As we ... we expect water infrastructure to become a top priority of our new political change ...
(Date:1/23/2017)... ... 2017 , ... Zachary Cattell, President of the Indiana Health ... expert at the 2017 Sector Summit hosted by Ivy Tech Community College on ... Dick, will feature an employer and an association representative from five of Indiana’s ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... applications. However, choosing the right method is paramount to success. Selecting an inappropriate ... in situations where multiple persons use the same equipment. Rare or expensive substances ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... "ProRandom is a set of camera tools ... create dynamic looks in Final Cut Pro X," said Christina Austin - CEO of Pixel ... to two layers of text with video footage. ProRandom works by using a virtual ...
Breaking Medicine News(10 mins):